Alkaline Phosphatase: Which Tests to Order Alongside It

What Alkaline Phosphatase Actually Measures

ALP is a family of enzymes that cleave phosphate groups from substrates at an alkaline pH. Four tissue-nonspecific isoforms (liver, bone, kidney, intestinal) and one placental isoform are encoded by distinct genes. Because the liver and bone isoforms together account for roughly 95% of circulating ALP in healthy adults, a serum ALP result reflects primarily the sum of hepatobiliary and skeletal activity. NIH reference values confirm this tissue distribution.

Why a Single ALP Number Is Rarely Enough

The test becomes clinically actionable only when paired results clarify tissue origin. A result of 300 U/L could mean primary biliary cholangitis, widespread Paget disease, bone metastases, or a third-trimester placental surge. Each condition demands a completely different clinical pathway, which is why the pairing strategy below matters.

Reference Ranges and Who Defines Them

Most U.S. Laboratories use 44 to 147 U/L as the adult reference interval, though some report 35 to 130 U/L. The ARUP Laboratories reference interval compendium notes that values vary by sex (slightly higher in males), age (higher in adolescents and the elderly), and assay platform. Children in active growth phases may show ALP levels 2 to 5x the adult upper limit of normal. That is physiologically normal and not a sign of disease. Clinicians should always compare a result against the sex- and age-stratified reference range printed on the lab report, not a single universal cutoff.

The First Paired Test: GGT to Confirm Hepatobiliary Origin

When ALP is elevated, gamma-glutamyltransferase (GGT) is the single most informative add-on. GGT is not produced by bone tissue in clinically meaningful quantities. A 2019 review in Clinica Chimica Acta confirmed that co-elevation of ALP and GGT carries a sensitivity of approximately 85% for hepatobiliary disease, whereas an elevated ALP with a normal GGT strongly points toward a skeletal or placental source.

How to Interpret the ALP-GGT Combination

• ALP high, GGT high: pursue hepatobiliary workup (biliary obstruction, PBC, PSC, drug-induced liver injury).
• ALP high, GGT normal: pivot immediately to a bone panel (see section below).
• ALP normal, GGT high: isolated GGT elevation most often reflects alcohol use or microsomal enzyme induction; ALP adds little here.

GGT Thresholds That Matter

GGT reference ranges are sex-dependent. The FDA-approved package labeling for ursodeoxycholic acid in primary biliary cholangitis cites baseline GGT values often exceeding 300 U/L in treatment trials, providing a clinical benchmark for severe cholestasis. A GGT between 1x and 3x the upper limit of normal with ALP at 1.5 to 3x suggests mild intrahepatic cholestasis; GGT above 10x with rising ALP warrants same-day imaging.

Full Hepatobiliary Panel: What Else to Order When GGT Is High

When both ALP and GGT are elevated, a complete hepatobiliary assessment requires several additional tests ordered simultaneously rather than sequentially, because waiting for each result before ordering the next adds weeks to diagnosis.

Bilirubin (Total and Direct)

Total bilirubin separates obstructive from non-obstructive cholestasis. Direct (conjugated) bilirubin above 50% of total suggests biliary obstruction or hepatocellular dysfunction. The AASLD Practice Guidance on Primary Sclerosing Cholangitis (2023) lists total bilirubin as a core prognostic variable in all cholestatic liver conditions.

ALT and AST

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) reflect hepatocellular injury rather than cholestasis. If ALP and GGT are both elevated but ALT and AST are normal or mildly elevated (less than 3x the upper limit of normal), the picture is predominantly cholestatic. ALT and AST more than 10x the upper limit of normal with a modestly elevated ALP suggests acute hepatocellular injury with secondary cholestasis, a pattern seen in acute viral hepatitis or ischemic hepatitis. A landmark NEJM review of drug-induced liver injury uses this ALT-to-ALP ratio (called the R-ratio) to classify liver injury patterns: R above 5 = hepatocellular, R below 2 = cholestatic, R between 2 and 5 = mixed.

Albumin and Prothrombin Time

Albumin and PT/INR measure synthetic function. They are normal in early or isolated biliary obstruction but fall as hepatocellular reserve deteriorates. Both are included in the Child-Pugh and MELD scoring systems used to stage chronic liver disease severity.

Antimitochondrial Antibody (AMA)

When the cholestatic pattern persists and no mechanical obstruction is visible on imaging, antimitochondrial antibody (AMA) should be ordered. AMA is positive in roughly 95% of patients with primary biliary cholangitis (PBC). The AASLD PBC Practice Guidance (2019) states that a positive AMA-M2 with a compatible clinical picture establishes PBC without liver biopsy.

Abdominal Ultrasound

Labs do not replace imaging in this workup. Right-upper-quadrant ultrasound is the first-line imaging study for elevated ALP and GGT per ACG guidelines on the evaluation of abnormal liver chemistries. Biliary dilation on ultrasound shifts the differential immediately toward mechanical obstruction (choledocholithiasis, stricture, cholangiocarcinoma) and guides the decision to proceed to MRCP or ERCP.

The Bone Panel: What to Order When GGT Is Normal

An elevated ALP with a normal GGT should trigger a focused skeletal workup. Bone is the only non-hepatic tissue that produces ALP at concentrations high enough to substantially raise serum levels in non-pregnant, non-adolescent adults.

Serum Calcium and Phosphate

These are the first two bone-related add-ons. Hypercalcemia with elevated ALP points toward primary hyperparathyroidism, bone metastases, or vitamin D toxicity. Hypophosphatemia with high ALP can indicate osteomalacia or hyperparathyroidism. NIH MedlinePlus electrolyte panels outline expected reference ranges for clinical comparison.

Parathyroid Hormone (PTH)

PTH drives bone turnover and directly stimulates osteoblast activity, raising bone-specific ALP. An elevated intact PTH with high calcium and elevated ALP is diagnostic of primary hyperparathyroidism until proven otherwise. The Endocrine Society Clinical Practice Guideline on Primary Hyperparathyroidism (2022) recommends ALP as part of the baseline biochemical panel at diagnosis, precisely because skeletal involvement correlates with ALP elevation.

25-Hydroxyvitamin D

Vitamin D deficiency produces secondary hyperparathyroidism and increased bone turnover, raising bone-specific ALP. A 2011 meta-analysis in BMJ covering 65,000 subjects found an inverse association between 25-OH vitamin D levels and bone turnover markers, including ALP. Target repletion in most adults is 25-OH vitamin D above 30 ng/mL per Endocrine Society guidance.

Bone-Specific ALP Isoenzyme (BSAP)

When the source remains ambiguous after GGT and the above tests, bone-specific ALP fractionation by electrophoresis or immunoassay directly quantifies skeletal contribution. BSAP is elevated in Paget disease of bone, bone metastases, and renal osteodystrophy. A study in the Journal of Bone and Mineral Research validated BSAP as a more sensitive marker of osteoblast activity than total ALP, with a coefficient of variation below 6% on modern immunoassays.

Serum Protein Electrophoresis (SPEP)

If bone metastases or myeloma are in the differential, SPEP adds detection of monoclonal proteins. Multiple myeloma can produce lytic bone lesions with paradoxically normal or low ALP because osteoblast suppression is a hallmark of the disease. Normal or low ALP in a patient with bone pain and hypercalcemia should raise this suspicion. A review in Blood covers ALP behavior in myeloma bone disease.

ALP Isoenzyme Fractionation: When and How

Isoenzyme testing separates total ALP into its tissue-of-origin components using heat stability, electrophoresis, or monoclonal immunoassay. Heat stability is the oldest method: bone-ALP is heat-labile (inactivated at 56°C for 15 minutes), while liver-ALP is relatively heat-stable. Electrophoresis provides better resolution and can detect placental and intestinal bands. Immunoassay is the most specific for BSAP.

Order isoenzyme fractionation when:

1. ALP is elevated, GGT is normal, and calcium/phosphate/vitamin D do not explain the elevation.
2. ALP is elevated in a patient with both known liver disease and known bone disease (dual-source ambiguity).
3. ALP is markedly elevated (more than 4x upper limit of normal) without an obvious clinical explanation.

The College of American Pathologists recommends fractionation as the definitive next step in unexplained ALP elevation before committing to expensive or invasive workups.

Thyroid Function and ALP: An Underappreciated Connection

Thyroid hormones regulate bone turnover. Hyperthyroidism accelerates osteoclast and osteoblast activity simultaneously, raising bone-specific ALP. A study published in JCEM found that ALP returned to normal within three to six months of restoring euthyroidism, confirming a direct causal relationship. TSH should be part of the ALP workup in any patient without an immediately obvious hepatobiliary or primary skeletal explanation, particularly in women over 50 where subclinical hyperthyroidism is prevalent.

Hypothyroidism, conversely, reduces bone turnover and is one of the causes of low ALP.

Low Alkaline Phosphatase: The Overlooked Abnormality

Most clinical algorithms focus on elevated ALP, but a below-normal result also has differential diagnoses that require targeted testing.

Causes of Low ALP

• Hypophosphatasia: a rare genetic disorder of tissue-nonspecific alkaline phosphatase (TNSALP), the same enzyme. Diagnosis requires plasma pyridoxal-5-phosphate (PLP) and urine phosphoethanolamine, both of which accumulate when ALP activity is absent. The NIH GeneReviews entry on hypophosphatasia outlines diagnostic criteria.
• Zinc deficiency: zinc is a cofactor for ALP activity. Serum zinc below 70 mcg/dL may suppress ALP even when enzyme protein is present. A trial in the American Journal of Clinical Nutrition showed ALP normalization within four weeks of zinc supplementation in deficient subjects.
• Hypothyroidism: TSH above 10 mIU/L is associated with ALP at or below the lower reference limit in multiple cohort studies.
• Pernicious anemia / severe B12 deficiency: ALP may be low due to reduced red cell turnover and bone marrow activity.

Paired Tests for Low ALP

Order zinc, TSH, B12, folate, and phosphate simultaneously. If hypophosphatasia is suspected (especially in a patient with stress fractures, dental anomalies, or a family history), TNSALP gene sequencing and PLP are the definitive next steps.

Hormonal Therapy, GLP-1 Agonists, and ALP

Patients on hormone-therapy protocols at HealthRX may show ALP changes that reflect therapy effects rather than primary liver or bone disease.

Estrogen and ALP

Oral estrogen raises sex-hormone-binding globulin and alters hepatic enzyme induction. Transdermal estrogen has a smaller first-pass hepatic effect. A trial in Menopause (2017) found that oral estradiol raised ALP by a mean of 12 U/L at six months compared with transdermal estradiol, which produced no significant change. If a patient on oral HRT has a mildly elevated ALP with normal GGT, switching to transdermal delivery and rechecking in eight weeks is a reasonable first step before pursuing a hepatobiliary workup.

Testosterone Therapy and ALP

Supraphysiologic testosterone stimulates bone turnover. ALP may rise transiently in the first three to six months of testosterone therapy, particularly in men who were hypogonadal for years before treatment. This reflects bone anabolic activity rather than hepatotoxicity, provided GGT remains normal. A study in the Journal of Clinical Endocrinology and Metabolism confirmed transient ALP rises in hypogonadal men starting TRT, normalizing by month nine.

GLP-1 Receptor Agonists and Hepatic ALP

Semaglutide and tirzepatide reduce hepatic steatosis, which may lower ALP over time in patients with nonalcoholic fatty liver disease (NAFLD). The STEP-1 trial (N=1,961) showed 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo. A pre-specified liver sub-analysis from STEP-1 found that GLP-1-mediated weight loss correlated with reductions in liver enzyme abnormalities including ALP in subjects with baseline NAFLD features. Monitoring ALP at baseline and at three and six months is appropriate in patients starting semaglutide or tirzepatide who have a pre-existing elevated ALP.

How to Lower Elevated ALP: Targeted Approaches by Cause

There is no drug that lowers ALP directly in isolation. The correct approach is treating the underlying cause. Specific interventions by mechanism:

Biliary Obstruction and Cholestasis

Ursodeoxycholic acid (UDCA) 13 to 15 mg/kg/day is the standard of care for primary biliary cholangitis. The AASLD PBC guideline (2019) states that ALP normalization on UDCA at one year predicts improved transplant-free survival. Obeticholic acid 5 to 10 mg/day is FDA-approved as an add-on for patients with inadequate UDCA response, with the FDA prescribing information showing ALP reductions of 39% at 12 months versus 5% with placebo in the POISE trial (N=216).

Bone Disease

Bisphosphonates (e.g., alendronate 70 mg weekly, zoledronic acid 5 mg yearly) reduce osteoclast activity, secondarily lowering osteoblast-driven ALP. A key trial in NEJM of zoledronic acid for Paget disease showed ALP normalization in 89% of subjects at six months. Correcting vitamin D deficiency (cholecalciferol 1,000 to 4,000 IU/day depending on baseline level) reduces secondary hyperparathyroidism and normalizes bone-related ALP within three to six months.

Original Clinical Decision Framework: The ALP Source Localization Algorithm

The following step-by-step framework organizes the paired-test strategy into a practical clinical sequence for clinicians and patients reviewing results on the HealthRX platform:

Step 1. Confirm the elevation is real. Check whether the patient is pregnant, adolescent, or had a recent high-fat meal (intestinal ALP can transiently double post-meal). Repeat fasting ALP before proceeding if any of these apply.

Step 2. Order GGT simultaneously with any ALP recheck. The GGT result determines the entire branch of the workup tree.

Step 3a. GGT elevated. Order ALT, AST, total bilirubin, direct bilirubin, albumin, PT/INR, and right-upper-quadrant ultrasound within the same 24-hour window. Add AMA-M2 if cholestatic pattern persists without mechanical obstruction on imaging.

Step 3b. GGT normal. Order serum calcium, phosphate, 25-OH vitamin D, PTH, and TSH. Add bone-specific ALP isoenzyme if the above panel does not explain the elevation.

Step 4. If both Step 3a and Step 3b are inconclusive, fractionation by electrophoresis remains the decisive test to identify rare isoforms (placental, intestinal, Regan isoenzyme of malignancy).

Step 5. In HealthRX patients on HRT or TRT, reassess route of administration before initiating a full hepatobiliary workup for mild elevations (1 to 1.5x upper limit of normal) with normal GGT.

What a Normal ALP Does Not Rule Out

A normal total ALP does not exclude early hepatobiliary disease or early bone disease. Conditions where ALP may remain within range despite active pathology include:

• Early nonalcoholic steatohepatitis (NASH), where ALT rises before ALP.
• Multiple myeloma, where osteoclastic activity suppresses osteoblast-driven ALP.
• Early primary sclerosing cholangitis, where ALP can be intermittently normal early in the disease course.

The ACG guidelines on abnormal liver chemistries note that "no single liver biochemical test is both sensitive and specific enough to serve as a standalone screening tool," an observation that applies directly to ALP-based decision-making.